Mission-Driven Tech

When a woman doesn't complete Brachytherapy, she is almost 100% likely to experience cancer recurrence and death. In the US, Cervical Cancer recurrence costs the health system over $100M each year. For every 100 women who die, an additional 30 children also don’t survive childhood. At Mission-Driven Tech, we know today’s standard of care is unacceptable. We need new tools that keep women in treatment. —- ❓Did you know that only 8.8% of NIH-funded research is directed to women’s health and female founders raise 2% of all dollars invested in startups – we have to get creative. So, we’re inviting you in for an inside look at we’re building with our most recent presentation at the 2024 BrightEdge - American Cancer Society investor showcase. All through December, join our team here on LinkedIn as we share our story, vision and progress to modernize the cure for Cervical Cancer. credit to our Mission-Driven Tech team: Dr. Onyinye Balogun, MD MS, Eve McDavid, Julie Winzenried (Harn Pasco), Amanda Blake, Matthew De Remer Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: https://lnkd.in/eXYRRMBc 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

What's the scale of this problem? More than 660,000 women worldwide receive Cervical Cancer diagnoses each year. Advanced diagnoses requiring brachytherapy are rising among women in their prime earning and childbearing years. Yet, roughly 30% of patients will die without accessing and completing Brachytherapy and extreme disparities exist in who accesses treatment. —- ❓Did you know that only 8.8% of NIH-funded research is directed to women’s health and female founders raise 2% of all dollars invested in startups – we have to get creative. So, we’re inviting you in for an inside look at we’re building with our most recent presentation at the 2024 BrightEdge - American Cancer Society investor showcase. All through December, join our team here on LinkedIn as we share our story, vision and progress to modernize the cure for Cervical Cancer. credit to our Mission-Driven Tech team: Dr. Onyinye Balogun, MD MS, Eve McDavid, Julie Winzenried (Harn Pasco), Amanda Blake, Matthew De Remer Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: https://lnkd.in/eXYRRMBc 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

We're building our first product suite, MODERN BRACHYTHERAPY, to change today’s brachytherapy treatment paradigm. MODERN BRACHYTHERAPY, by Mission-Driven Tech includes: 🌸 The Blossom, a new medical device (in-development) 📚 BrachyStories, outcome improvement research (launched! ✅ ) --- ❓Did you know that only 8.8% of NIH-funded research is directed to women’s health and female founders raise 2% of all dollars invested in startups – so, we have to get creative. We’re inviting you in for an inside look at we’re building with our most recent presentation at the 2024 BrightEdge - American Cancer Society investor showcase. All through December, join our team daily here on LinkedIn as we share our story, vision and progress to modernize the cure for Cervical Cancer. cc: Dr. Onyinye Balogun, MD MS, Eve McDavid, Julie Winzenried (Harn Pasco), Amanda Blake, Matthew De Remer Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: https://lnkd.in/eXYRRMBc 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

In 2022, Eve McDavid, a former Google executive, and Dr. Onyinye Balogun, MD MS, a world renowned radiation oncologist, co-founded Mission-Driven Tech. Mission-Driven Tech is a Cervical Cancer innovation company. We build essential medical device technology to combat the field's 50-year STAGNANT survival rates. Despite #CervicalCancer being preventable, treatable and curable, lack of field funding is a leading cause of poor outcomes: without funding, scientific research that leads to innovation cannot happen. And because funding is scarce – only 8.8% of NIH-funded research is directed to women’s health and female founders raise 2% of all dollars invested in startups – we have to get creative. So, we’re inviting you in for an inside look at we’re building with our most recent presentation at the 2024 BrightEdge - American Cancer Society investor showcase. All through December, join our team daily here on LinkedIn as we share our story, vision and progress to modernize the cure for Cervical Cancer. cc: Julie Winzenried (Harn Pasco), Amanda Blake, Matthew De Remer Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: $25 purchase ➡️ 6 minutes of r&d 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

📌 OMG she's here!! Please welcome our Happy Cervix™ pin to the world! ⏰ Every $25 pin funds 6 minutes of engineering efforts on Modern Brachytherapy, our first product suite at Mission-Driven Tech. 🧠 Remember: 💵 Investment --> ⚒️ Research --> 💥 Innovation 🛍️ Pre-shop yours for January here: https://lnkd.in/eXusEKKz ➡️ Head to the Mission-Driven Tech LinkedIn page to learn more about the research & development work our retail products are funding.

40% of women don’t complete Brachytherapy, the cure for Cervical Cancer, because of this medical device. When a patient doesn't complete treatment, her tumor will recur and she will die. So why would anyone drop out from the cure for cancer? Late-stage diagnoses, ~70% of diagnoses, follow an 8-week, trip-part standard of care: Weeks 1-6: weekly chemotherapy infusions + daily external beam radiation Weeks 6-8: 5 brachytherapy procedures, 8-10 hours each Treatment extending any amount beyond 8 weeks -- even a single day -- produces a precipitous survival rate drop. At this very moment, Brachytherapy is performed in US clinics and around the world with the medical devices below, originally designed in the 1970s. These devices are inserted into the patient's vagina to access the cervix and be placed in the uterus. A radioactive seed travels through the device channels and administers radiation directly to the tumor. It disrupts the HPV virus and melts the tumor. But because these devices were designed 20 years before women's mandatory inclusion in clinical trials, the instruments don't properly fit the female anatomy, are inherently painful and create unsafe treatment conditions. Complications are common, often more expensive than the treatment: uterine perforation occurs in 20% of procedures (vs. to less than 1% perf rate in colonoscopy), leading to infections, delays in care and poor treatment outcomes. The devices are inserted and removed with insufficient anesthesia and pain control, meaning patients are often awake for these surgical procedures. Procedure pain is extreme and is likened to childbirth. Clinicians and patients alike describe the tools as "medieval torture devices." Patients who complete brachytherapy experience PTSD and extreme physical, sexual and mental health side effects. Brachytherapy practitioners who perform procedures report vicarious trauma and PTSD symptoms from witnessing patients endure procedures. The violent patient experience and diminished quality of life outcome is well-documented in medical literature and yet, unsafe practices persist. ... ❓Did you know that only 8.8% of NIH-funded research is directed to women’s health and female founders raise 2% of all dollars invested in startups? At Mission-Driven Tech, we have to be creative to fund our scientific research & development. All through December, join our team daily here on LinkedIn as we share our story, vision and progress to modernize the cure for #CervicalCancer. So, we’re inviting you in for an inside look at we’re building with our most recent presentation at the 2024 BrightEdge - American Cancer Society investor showcase. Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: https://lnkd.in/eXYRRMBc 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

While survival outcomes for all cancers have improved dramatically over the last 50 years, Cervical Cancer survival rates have remained stagnant. Remember: #CervicalCancer is preventable, treatable & curable. For comparison, over the same time horizon, Prostate Cancer, which only affects men, improved to almost 100% 5-year survival. ... ❓Did you know that only 8.8% of NIH-funded research is directed to women’s health and female founders raise 2% of all dollars invested in startups? At Mission-Driven Tech, we have to be creative to fund our scientific research & development. All through December, join our team daily here on LinkedIn as we share our story, vision and progress to modernize the cure for Cervical Cancer. cc: Julie Winzenried (Harn Pasco), Amanda Blake, Matthew De Remer Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: $25 purchase ➡️ 6 minutes of r&d 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

In 2020, Eve McDavid was an executive at Google when she survived a deadly Cervical Cancer diagnosis. In conjunction with six weekly chemotherapy infusions, Dr. Onyinye Balogun, MD MS designed & delivered five weeks of daily external beam radiation. Following chemoradiation, Dr. Balogun next administered five internal radiation procedures that cure #CervicalCancer known as Brachytherapy. Eve's treatment outcome was extraordinary and statistically unusual. And so the duo teamed up to co-found Mission-Driven Tech to scale better outcomes to women and physicians everywhere. cc: Julie Winzenried (Harn Pasco), Amanda Blake, Matthew De Remer Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: missiondriventech.com/shop 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

In 2022, Eve McDavid, a former Google executive, and Dr. Onyinye Balogun, MD MS, a world renowned radiation oncologist, co-founded Mission-Driven Tech. Mission-Driven Tech is a Cervical Cancer innovation company. We build essential medical device technology to combat the field's 50-year STAGNANT survival rates. Despite #CervicalCancer being preventable, treatable and curable, lack of field funding is a leading cause of poor outcomes: without funding, scientific research that leads to innovation cannot happen. And because funding is scarce – only 8.8% of NIH-funded research is directed to women’s health and female founders raise 2% of all dollars invested in startups – we have to get creative. So, we’re inviting you in for an inside look at we’re building with our most recent presentation at the 2024 BrightEdge - American Cancer Society investor showcase. All through December, join our team daily here on LinkedIn as we share our story, vision and progress to modernize the cure for Cervical Cancer. cc: Julie Winzenried (Harn Pasco), Amanda Blake, Matthew De Remer Moved to take action? 🎁 SHARE this post with your network 🛒 SHOP our Happy Cervix™ pin: $25 purchase ➡️ 6 minutes of r&d 💲 INVEST in Mission-Driven Tech: email welcome@missiondriventech.com

🌟 introducing our new Mission-Driven Tech Happy Cervix™ pin! 💡 each $25 purchase funds 6 minutes of research & development on Modern Brachytherapy, our first MDT product suite 🛠️ Modern Brachytherapy includes: The Blossom, a modern medical device (in-development) and BrachyStories, outcome improvement research (launched). 🎁 our Happy Cervix™ pin is the perfect gift to show your commitment to #CervicalCancer #innovation and #elimination. 🟠 oh, and she's delightfully adorable, too :) 🛒 add to cart here: https://lnkd.in/eXusEKKz It's a team effort every time -- thank you Amanda Blake, Julie Winzenried (Harn Pasco), Matthew De Remer, @Melissa Rose & Dr. Onyinye Balogun, MD MS! #womenshealth #femalefounders #startup #breakthedam #fundeliminationnow